Online Database of Chemicals from Around the World

Biapenem
[CAS# 120410-24-4]

Top Active Suppliers
Wuhan Kemi-works Chemical Co., Ltd. China Inquire  
+86 (27) 8573-6489
info@kemiworks.net
sales@kemiworks.com
Chemical manufacturer
chemBlink premium supplier since 2011
Identification
Classification API >> Synthetic anti-infective drugs >> Antifungal drugs
Name Biapenem
Synonyms 6-[[(4R,5S,6S)-2-Carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium inner salt
Molecular Structure CAS # 120410-24-4 (155835-09-9), Biapenem, 6-[[(4R,5S,6S)-2-Carboxy-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium inner salt
Molecular Formula C15H18N4O4S
Molecular Weight 350.39
CAS Registry Number 120410-24-4 (155835-09-9)
SMILES C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1SC3CN4C=NC=[N+]4C3)C(=O)[O-])[C@@H](C)O
Properties
Solubility >5 mg/mL (H2O, warmed)
Safety Data
Hazard Symbols symbol   GHS07 Warning    Details
Hazard Statements H302    Details
Precautionary Statements P280-P305+P351+P338    Details
SDS Available
up Discovory and Applicatios
Biapenem is a broad-spectrum antibiotic belonging to the class of carbapenems, which are known for their potent bactericidal activity against a wide range of gram-positive and gram-negative bacteria. First discovered in the 1980s, biapenem was developed as part of the ongoing efforts to create new antibiotics that could overcome the growing problem of bacterial resistance to traditional antibiotics. As a carbapenem, biapenem works by inhibiting bacterial cell wall synthesis, a mechanism that is crucial for the bacteria's survival. Its chemical structure features a beta-lactam ring, which is essential for its antibacterial action, and a sulfur atom in the side chain, which distinguishes it from other carbapenems like imipenem.

The synthesis of biapenem involves the formation of a beta-lactam ring through a series of chemical reactions, where the precursor compounds are subjected to cyclization reactions in the presence of specific catalysts. The synthesis process has been optimized over the years, with improvements focusing on increasing yield, reducing costs, and ensuring the stability of the final product. Biapenem is typically administered via injection or intravenous infusion in clinical settings, where it is used to treat a variety of infections, including respiratory, urinary tract, and intra-abdominal infections, as well as skin and soft tissue infections.

One of the major advantages of biapenem over older antibiotics is its resistance to hydrolysis by many beta-lactamases, enzymes produced by certain bacteria to degrade antibiotics. This makes biapenem an effective option against drug-resistant bacterial strains, including those that produce extended-spectrum beta-lactamases (ESBLs). This feature gives biapenem a significant role in the treatment of infections caused by multi-drug-resistant pathogens, which are becoming an increasing challenge in healthcare settings worldwide.

In addition to its antibacterial activity, biapenem has been shown to have a relatively low toxicity profile, making it a safer option for patients compared to some other antibiotics in its class. However, as with all antibiotics, its use must be carefully managed to prevent the development of further resistance. Biapenem is often reserved for severe or hospital-acquired infections, and its use is typically guided by culture and sensitivity testing to ensure it is effective against the specific pathogen causing the infection.

Biapenem is not only an important therapeutic agent but also plays a key role in the ongoing research into carbapenem antibiotics. Scientists are continually studying biapenem's mechanisms of action, its effectiveness against emerging resistant strains, and its potential use in combination therapies. Ongoing studies are also exploring the possibility of biapenem being used in the treatment of infections caused by resistant strains of Mycobacterium tuberculosis, as well as its role in treating infections in immunocompromised patients.

In summary, biapenem is a vital antibiotic in the fight against bacterial infections, particularly those caused by resistant pathogens. Its discovery and continued development highlight the importance of advancing antibiotic therapies in response to the growing challenge of antimicrobial resistance.
Market Analysis Reports
List of Reports Available for Biapenem
Related Products
Bicyclo[2.2.1]heptan-2-yl dimethoxy-(methyl)silane  BHMT  B-HT 958  BI 2536  BI 847325  1,1'-Biadamantane  Biafungin acetate  9,9'-Bianthracene  1-(7-[9,9'-Bianthracen]-10-yl-9,9-dioctyl-9H-fluoren-2-yl)pyrene  Bianthrone  3,8''-Biapigenin  (4R)-[4,4'-Bi-1,3-benzodioxole]-5,5'-diylbis[bis[3,5-bis(1,1-dimethylethyl)-4-methoxyphenyl]phosphine  [(4R)-[4,4'-Bi-1,3-benzodioxole]-5,5'-diyl]bis[diphenylphosphine]  Bibenzyl  2-Bibenzylcarboxylic acid  BIBF-1120  BIBF 1202  BIBP 3226 trifluoroacetate  BIBR 1532  BIBW 2992